A5048336588- Platelet Disorders and Treatments
- Hemophilia Treatment and Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Blood groups and transfusion
- Blood Coagulation and Thrombosis Mechanisms
- Blood properties and coagulation
- Antiplatelet Therapy and Cardiovascular Diseases
- Hemostasis and retained surgical items
- Congenital Diaphragmatic Hernia Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Neonatal Health and Biochemistry
- Cardiovascular Issues in Pregnancy
Nara Medical University
2014-2023
Nara City Hospital
2023
Abstract Introduction Type 2A von Willebrand disease (VWD) is common in type‐2 group caused by qualitative deficiency of factor (VWF). Emicizumab a bispecific antibody that mimics activated VIII (FVIIIa) cofactor function, and emicizumab prophylaxis substantially reduces bleeding patients with haemophilia A. It unknown whether affects thrombus formation type VWD characterized not only low FVIII levels but also the impaired platelet adhesion aggregation. Aim To examine coagulant potential...
Type 1 and type 3 von Willebrand disease (VWD) are caused by partial complete, quantitative deficiency of factor (VWF), respectively, (F)VIII/VWF complex concentrates used for haemostatic treatment. Emicizumab, mimics activated FVIII, reduces bleeding in haemophilia A patients. The effects emicizumab on haemostasis both types VWD remain to be fully established, however.To examine the thrombogenesis VWD.Perfusion chamber experiments under high shear conditions (2500 s-1 ) combined with...
Red blood cells (RBCs) contribute to hemostasis under blood-flow, and anemia might a hemorrhagic diathesis. The majority of current laboratory techniques assess do not consider the effects RBCs. An assay determine role RBCs in could be beneficial for clinical management.To investigate influence hemostasis.Hemostasis was investigated using novel microchip flow-chamber system (T-TAS® ) an anemic patient with von Willebrand disease. Subsequently, total thrombus analysis (T-TAS) were examined...
Emicizumab is a bispecific antibody to factor (F) IXa and FX that mimics the FVIIIa cofactor function. prophylaxis markedly decreases bleeding episodes in patients with hemophilia A (PwHAs), irrespective of presence FVIII inhibitors. However, thrombotic microangiopathy (TMA) was reported when repeated high doses activated prothrombin complex concentrates (aPCC) were concomitantly used emicizumab. Although bypassing agents (BPAs) are vital hemostatic treatment for PwHAs inhibitors, mechanism...
Abstract Background Von Willebrand factor (VWF) and VIII (FVIII) complex play a pivotal role in hemostasis. A deficiency or defect of VWF causes von disease (VWD). Recombinant (r)VWF product has proved to be effective for hemostatic treatment VWD, but limited information is available on their moderating thrombus formation under flow condition. We aimed assess the presence rVWF combined with rFVIII pegylated-extended half-life (peg-EHL-rFVIII) VWD whole blood high shear flow. Methods...